Platform Clinical Study for Conquering Scleroderma

Key facts

Sponsor

Scleroderma Research Foundation, Inc.

Principal Investigator

Kevin O'Shea, Psy.D

Scleroderma Research Foundation

Intervention

Amlitelimab(drug)

Enrollment

400 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Study locations (30)

• University of Alabama - Division of Pulmonary and Critical Care Medicine, Birmingham, Alabama, United States
• Keck School of Medicine at USC Medical Center, Los Angeles, California, United States
• Cedars-Sinai Medical Center, Los Angeles, California, United States
• University of California, Los Angeles (UCLA) Ronald Reagan Medical Center, Los Angeles, California, United States
• Stanford University Medical Center, Palo Alto, California, United States
• Yale University School of Medicine - Epilepsy, New Haven, Connecticut, United States
• Georgetown University Medical Center - Department of Rheumatology, Washington D.C., District of Columbia, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• Northwestern University, Chicago, Illinois, United States
• The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
• University of Kansas School of Medicine, Kansas City, Kansas, United States
• Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Boston University (BU), Boston, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Sanofi · Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07473154
  Controlling Hyperactive Immunity With Long-lived Lymphocytes
  Quell Therapeutics Limited
• RECRUITINGPHASE1, PHASE2NCT06947473
  Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT05029336
  Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
  Stephan Grupp MD PhD
• RECRUITINGPHASE2NCT07047690
  A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
  Galderma R&D
• RECRUITINGPHASE2NCT07287670
  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
  Mediar Therapeutics
• RECRUITINGNCT07256418
  Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
  Centre Hospitalier Universitaire Dijon
• RECRUITINGPHASE1NCT07295847
  A Study of AZD0120 in Autoimmune Diseases
  AstraZeneca
• RECRUITINGNANCT07292961
  Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
  Hacettepe University

See all trials for Diffuse cutaneous systemic sclerosis →